Live Analyst Rating Changes 23245 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Nico Chen
DBS

Nico Chen

DBS
Wall Street Analyst
★★★☆☆
#1051
on 13Foresight · ranked by our own returns
68%
Success Rate
+15.0%
Average Return
25 of 37 calls profitable · -3.5% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 68% of Nico Chen's ratings turned a profit when each position was held for 1 year — averaging +15.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

15 Buy 8 Hold 0 Sell
Nico's Stock Coverage 37 ratings · 2026-08-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
HK:2252
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
 Jul 23, 2026 BUY Strong Buy
1 analyst
 — +14.8% ·
SYK
Stryker
 Mar 18, 2026 BUY Strong Buy
+6.1% avg upside
37 analysts
$450.00
29.20% Upside
 +0.5% ·
MDT
Medtronic
 Mar 18, 2026 HOLD Buy
+6.9% avg upside
38 analysts
$90.00
0.83% Downside
 +4.4% ·
ISRG
Intuitive Surgical
 Mar 18, 2026 HOLD Strong Buy
+19.9% avg upside
36 analysts
$480.00
19.60% Upside
 -16.0% ·
ATR
AptarGroup
 Mar 18, 2026 BUY Strong Buy
+5.4% avg upside
14 analysts
$170.00
26.26% Upside
 +9.8% ·
CH:DAE
Daetwyler Holding
 Mar 17, 2026 BUY Strong Buy
+36.5% avg upside
4 analysts
$190.00
38.89% Upside
 -5.3% ·
ABBV
AbbVie
 Feb 25, 2026 HOLD Strong Buy
-4.3% avg upside
46 analysts
$230.00
8.01% Downside
 +11.3% ·
JNJ
Johnson & Johnson
 Feb 24, 2026 HOLD Strong Buy
-9.2% avg upside
39 analysts
$240.00
7.60% Downside
 +6.1% ·
DE:SHL
Siemens Healthineers AG
 Feb 24, 2026 BUY Buy
+25.1% avg upside
24 analysts
$52.00
32.39% Upside
 -6.3% ·
CH:LONN
Lonza Group Ltd
 Feb 02, 2026 BUY Strong Buy
+13.0% avg upside
21 analysts
$670.00
17.43% Upside
 +9.7% ·
WST
West Pharmaceutical Services
 Jan 28, 2026 BUY Strong Buy
+4.4% avg upside
18 analysts
$320.00
8.95% Downside
 +49.1% ·
GEHC
GE Healthcare Technologies Inc
 Jan 28, 2026 BUY Strong Buy
+13.0% avg upside
22 analysts
$100.00
37.44% Upside
 -8.7% ·
MRNA
Moderna
 Jan 28, 2026 HOLD Hold
+17.8% avg upside
38 analysts
$45.00
25.72% Downside
 +40.6% ·
MRK
Merck & Company
 Jan 28, 2026 BUY Strong Buy
-0.7% avg upside
43 analysts
$130.00
0.41% Downside
 +23.8% ·
AMGN
Amgen
 Jan 22, 2026 BUY Buy
-23.9% avg upside
57 analysts
$400.00
3.42% Downside
 +21.9% ·
GB:0QIU
Novo Nordisk
 Jan 22, 2026 HOLD Hold
+33.5% avg upside
29 analysts
$380.00
22.86% Upside
 · ·
REGN
Regeneron
 Jan 22, 2026 BUY Strong Buy
-2.1% avg upside
58 analysts
$910.00
14.09% Upside
 +4.1% ·
VRTX
Vertex Pharmaceuticals
 Jan 19, 2026 BUY Strong Buy
-15.5% avg upside
62 analysts
$540.00
1.88% Upside
 +19.6% ·
LLY
Eli Lilly & Co
 Jan 02, 2026 BUY Strong Buy
-13.8% avg upside
48 analysts
$1333.00
9.70% Upside
 +13.6% ·
HK:2269
Wuxi Biologics (Cayman)
 Aug 26, 2025 HOLD Buy
-17.5% avg upside
4 analysts
$36.00
20.75% Downside
 +44.4% ·
SNY
Sanofi
 Jun 03, 2025 BUY Strong Buy
+69.5% avg upside
20 analysts
$66.00
51.58% Upside
 -9.1% ·
PFE
Pfizer
 May 30, 2025 BUY Buy
+25.8% avg upside
45 analysts
$30.00
12.64% Upside
 +19.2% ·
GILD
Gilead Sciences
 May 30, 2025 BUY Strong Buy
-12.1% avg upside
66 analysts
$125.00
7.96% Downside
 +25.4% ·
BDX
Becton Dickinson
 May 21, 2025 HOLD Buy
+8.3% avg upside
25 analysts
 — +10.0% ·
HCA
HCA Healthcare
 May 21, 2025 HOLD Buy
-0.9% avg upside
36 analysts
 — +3.5% ·
BSX
Boston Scientific
 Mar 31, 2025 BUY Strong Buy
+32.8% avg upside
38 analysts
$130.00
154.05% Upside
 -37.8% ·
SHTDY
Sinopharm Group Co
 Mar 03, 2025 HOLD Buy
2 analysts
 — +10.8% ·
HK:0853
MicroPort Scientific
 Mar 03, 2025 HOLD Hold
+127.6% avg upside
2 analysts
 — +34.8% ·
JP:4543
Terumo
 Oct 15, 2024 BUY Strong Buy
+45.5% avg upside
5 analysts
$3200.00
23.15% Upside
 -13.7% ·
HK:1066
Shandong Weigao Group Medical Polymer Co
 Sep 02, 2024 BUY Strong Buy
+88.5% avg upside
1 analyst
$6.40
88.55% Upside
 +50.2% ·
HK:1681
Consun Pharmaceutical Group Ltd.
 Aug 22, 2024 BUY Strong Buy
1 analyst
 — +179.6% ·
HK:1801
Innovent Biologics
 Aug 01, 2024 HOLD Strong Buy
+6.2% avg upside
7 analysts
 — +136.9% ·
HK:1099
Sinopharm Group Co
 Mar 26, 2024 BUY Strong Buy
+75.0% avg upside
1 analyst
$29.30
75.00% Upside
 -5.6% ·
AMPH
Amphastar Pharmaceuticals
 Nov 24, 2023 BUY Hold
+25.7% avg upside
11 analysts
$55.00
169.28% Upside
 -20.1% ·
STVN
Stevanato Group
 Nov 03, 2023 HOLD Strong Buy
+31.2% avg upside
13 analysts
$30.00
42.58% Upside
 -26.3% ·
DE:GXI
Gerresheimer
 Oct 10, 2023 BUY Buy
+130.0% avg upside
16 analysts
$120.00
343.20% Upside
 -19.5% ·
CRL
Charles River Labs
 Aug 22, 2023 HOLD Strong Buy
-16.3% avg upside
35 analysts
$188.70
33.06% Downside
 +0.5% ·
🔒 32 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Nico Chen — Frequently Asked Questions
How accurate are Nico Chen's stock ratings?
Based on the calls 13Foresight could measure, about 68% of Nico's ratings were profitable over a one-year hold, with an average return of +14.6% per rating, or -3.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Nico ranked on 13Foresight?
Nico Chen is currently ranked #1051 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Nico cover?
Nico most recently has ratings on HK:2252, SYK, MDT, ISRG, ATR, CH:DAE, ABBV, JNJ, DE:SHL, CH:LONN, WST, GEHC and 25 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.